» Articles » PMID: 10500065

Mapping of a Target Region of Allelic Loss to a 0.5-cM Interval on Chromosome 22q13 in Human Colorectal Cancer

Overview
Specialty Gastroenterology
Date 1999 Sep 29
PMID 10500065
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Chromosomal allelic losses have a varying frequency in colorectal cancer. The aim of this study was to define the target region of allelic loss on chromosome 22q in human colorectal carcinogenesis.

Methods: Fifty-seven pairs of matched normal colonic mucosa and tumor specimens from patients with colorectal cancer, as well as 15 colon cancer-derived cell lines, were genotyped using 15 microsatellite markers spanning chromosome 22q. A potential candidate gene was analyzed by a single-strand conformation polymorphism (SSCP)/direct DNA sequencing approach.

Results: After excluding 7 tumors with evidence of microsatellite instability, allelic loss was observed in 11 of the informative tumors (22%), 5 of which exhibited losses in all informative loci. The remaining 6 tumors showed variable patterns of partial allelic loss on chromosome 22q, thereby localizing a minimal region of allelic deletion between markers D22S1171 and D22S928. Physical mapping showed that this interval was 0.57 cM consisting of approximately 425 kilobases. Database searches identified the NBK/BIK gene, a proapoptotic BCL-2 family member, as a candidate gene in that region. However, SSCP/sequencing analysis excluded mutations of this gene.

Conclusions: This study provides evidence for the involvement of putative tumor-suppressor gene(s) on chromosome 22q in human colorectal carcinogenesis. The identification of a 0.5-cM interval serves as the basis for the isolation of such a gene by positional cloning.

Citing Articles

Loss of RAB25 Cooperates with Oncogenes in the Transformation of Human Mammary Epithelial Cells (HMECs) to Give Rise to Claudin-Low Tumors.

Joshi P, Ayyagari V, Kandel S, Modur V, Iqbal M, Robinson K Biomed Res Int. 2024; 2024:8544837.

PMID: 38803515 PMC: 11129910. DOI: 10.1155/2024/8544837.


Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population.

Felicio P, Bidinotto L, Melendez M, Grasel R, Campacci N, Galvao H Oncotarget. 2018; 9(44):27525-27534.

PMID: 29938003 PMC: 6007956. DOI: 10.18632/oncotarget.25537.


The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer.

Pandya V, Glubrecht D, Vos L, Hanson J, Damaraju S, Mackey J Oncotarget. 2016; 7(22):33272-85.

PMID: 27120789 PMC: 5078093. DOI: 10.18632/oncotarget.8924.


Proteasome inhibition enhances the killing effect of BikDD gene therapy.

Sun Y, Ponz-Sarvise M, Chang S, Chang W, Chen C, Hsu J Am J Transl Res. 2015; 7(2):319-27.

PMID: 25901200 PMC: 4399095.


Prognostic Impact of del(17p) and del(22q) as assessed by interphase FISH in sporadic colorectal carcinomas.

Gonzalez-Gonzalez M, Munoz-Bellvis L, Mackintosh C, Fontanillo C, Gutierrez M, Abad M PLoS One. 2012; 7(8):e42683.

PMID: 22912721 PMC: 3422354. DOI: 10.1371/journal.pone.0042683.